Subcellular targeting of therapeutic proteins

Details Subcellular targeting of therapeutic proteins Subcellular targeting of therapeutic proteins

2002-04-30

2008-07-08

Stucker, Jeffrey (Department: 1649)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S008100, C424S185100

Reexamination Certificate

active

07396811

ABSTRACT:
Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.

REFERENCES:
patent: 4309776 (1982-01-01), Berguer
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4749570 (1988-06-01), Poznansky
patent: 4801575 (1989-01-01), Pardridge
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 5236838 (1993-08-01), Rasmussen et al.
patent: 5258453 (1993-11-01), Kopecek et al.
patent: 5356804 (1994-10-01), Desnick et al.
patent: 5405942 (1995-04-01), Bell et al.
patent: 5470828 (1995-11-01), Ballard et al.
patent: 5476779 (1995-12-01), Chen et al.
patent: 5549892 (1996-08-01), Friedman et al.
patent: 5580757 (1996-12-01), Desnick et al.
patent: 5633234 (1997-05-01), August et al.
patent: 5633235 (1997-05-01), Townsend et al.
patent: 5704910 (1998-01-01), Humes
patent: 5736363 (1998-04-01), Edwards et al.
patent: 5798366 (1998-08-01), Platt et al.
patent: 5817623 (1998-10-01), Ishii
patent: 5817789 (1998-10-01), Heartlein et al.
patent: 5827703 (1998-10-01), Debs et al.
patent: 5854025 (1998-12-01), Edwards et al.
patent: 5977307 (1999-11-01), Friden et al.
patent: 5981194 (1999-11-01), Jefferies et al.
patent: 6020144 (2000-02-01), Gueiros-Filho et al.
patent: 6027921 (2000-02-01), Heartlein et al.
patent: 6066626 (2000-05-01), Yew et al.
patent: 6083725 (2000-07-01), Selden et al.
patent: 6118045 (2000-09-01), Reuser et al.
patent: 6226603 (2001-05-01), Freire et al.
patent: 6235874 (2001-05-01), Wu et al.
patent: 6262026 (2001-07-01), Heartlein et al.
patent: 6270989 (2001-08-01), Treco et al.
patent: 6273598 (2001-08-01), Keck et al.
patent: 6281010 (2001-08-01), Gao et al.
patent: 6284875 (2001-09-01), Turpen et al.
patent: 6329501 (2001-12-01), Smith et al.
patent: 6344436 (2002-02-01), Smith et al.
patent: 6348194 (2002-02-01), Huse et al.
patent: 6441147 (2002-08-01), Turpen et al.
patent: 6451600 (2002-09-01), Rasmussen et al.
patent: 6455494 (2002-09-01), Jefferies et al.
patent: 6472140 (2002-10-01), Tanzi et al.
patent: 6537785 (2003-03-01), Canfield
patent: 6566099 (2003-05-01), Selden et al.
patent: 6569661 (2003-05-01), Qin et al.
patent: 6596500 (2003-07-01), Kang et al.
patent: 2001/0006635 (2001-07-01), Bennett et al.
patent: 2001/0025026 (2001-09-01), Heartlein et al.
patent: 2002/0013953 (2002-01-01), Reuser et al.
patent: 2002/0081654 (2002-06-01), Sandrin et al.
patent: 2002/0110551 (2002-08-01), Chen
patent: 2002/0142299 (2002-10-01), Davidson et al.
patent: 2003/0004236 (2003-01-01), Meade
patent: 2003/0021787 (2003-01-01), Hung et al.
patent: 2003/0077806 (2003-04-01), Selden et al.
patent: 2003/0082176 (2003-05-01), LeBowitz et al.
patent: 2004/0029779 (2004-02-01), Zhu et al.
patent: 2004/0081645 (2004-04-01), Van Bree et al.
patent: 2004/0248262 (2004-12-01), Koeberl
patent: 2005/0026823 (2005-02-01), Zankel et al.
patent: 2005/0058634 (2005-03-01), Zhu
patent: 0599303 (1994-06-01), None
patent: WO 91/04014 (1991-04-01), None
patent: WO 93/06216 (1993-04-01), None
patent: WO 95/02421 (1995-01-01), None
patent: WO 00/53730 (2000-09-01), None
patent: WO 01/19955 (2001-03-01), None
patent: WO 02/44355 (2002-06-01), None
patent: WO 02/056907 (2002-07-01), None
patent: WO 02/087510 (2002-11-01), None
patent: WO 03/032727 (2003-04-01), None
patent: WO 03/032913 (2003-04-01), None
patent: WO 03/057179 (2003-07-01), None
patent: WO 03/102583 (2003-12-01), None
Kerr et al. (1999).I Comparison of recombinant and synthetically formed monoclonal antibody beta lactamase conjugates for anticancer prodrug activation. Bioconjugate Chemistry, 10, 1084-1089.
Dobrenis et al. (1992). Neuronal lysosomal enzyme replacement using fragment C of tetanus toxin. PNAS. 89, 2297-2301.
Auletta et al. (1992). Receptor-mediated endocytosis and degradation of insulin-like growth factor I and II in neonatal rat astrocytes. Journal of Neuroscience Research. 31, 14-20.
Russell et al. (1999). Cinical Genetics. 389-394.
Brady et al (2001). J. Inherit. Metab. 24. 18-24.
Allen et al., “Metabolic Correction of Fucosidosis Lymphoid Cells By Galaptin-α-L-Fucosidase Conjugates,”Biochemical and Biophysical Research Communications, 172(1):335-340 (Oct. 15, 1990).
Authier et al., “In vitro endosome-lysosome transfer of dephosphorylated EGF receptor and Shc in rat liver,”FEBS Letters, 00:25-31 (1999).
Bach et al., “Binding of Mutants of Human Insulin-like Growth Factor II to Insulin-like Growth Factor Binding Proteins 1-6,”The Journal of Biological Chemistry, 268(12):9246-9254 (May 5, 1993).
Baxter, R.C., “Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities,”Am. J. Physiol. Endocrinol. Metab., 278:E967-E976 (2000).
Bickel et al., “Delivery of peptides and proteins through the blood-brain barrier,”Advanced Drug Delivery Reviews, 46:247-279 (2001).
Bijsterbosch et al., “Native and modified lipoproteins as drug delivery systems,”Advanced Drug Delivery Reviews, 5:231-251 (1990).
Birkenmeier et al., “Increased Life span and Correction of Metabolic Defects in Murine Mucopolysaccharidosis Type VII After Syngeneic Bone Marrow Transplantation,”Blood, 78(11):3081-3092 (1991).
Birkenmeier et al., “Murine Mucopolysaccharidosis Type VII, Characterization of a Mouse with β-Glucuronidase Deficiency,”J. Clin. Invest., 83:1258-1266 (Apr. 1989).
Braulke, T., “Type-2 IGF Receptor: A Multi-Ligand Binding Protein,”Horm. Metab. Res., 31:242-246 (1999).
Brown et al., “Structure of a functional IGF2R fragment determined from the anomalous scattering of sulfur,”The EMBO Journal, 21(5):1054-1062 (2002).
Bürgisser et al., “Mutants of Human Insulin-like Growth Factor II with Altered Affinities for the Type 1 and Type 2 Insulin-like Growth Factor Receptor,”The Journal of Biological Chemistry, 266(2):1029-1033 (Jan. 15, 1991).
Calhoun et al., “Fabry disease: Isolation of a cDNA clone encoding human α-galactosidase A,”Proc. Natl. Acad. Sci. USA, 82:7364-7368 (Nov. 1985).
Cascieri et al., “Structural Analogs of Human Insulin-like Growth Factor (IGF) I with Altered Affinity for Type 2 IGF Receptors,”The Journal of Biological Chemistry, 264(4):2199-2202 (Feb. 5, 1999).
Daly et al., “Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease,”Proc. Natl. Acad. Sci. USA, 96:2296-2300 (Mar. 1999).
Dobrenis et al., “Neuronal Lysosomal Enzyme Replacement Using Fragment C of Tetanus Toxin,”Proc. Natl. Acad. Sci. USA, 89:2297-2301 (Mar. 1992).
Forbes et al., “Contribution of Residues A54 and L55 of the Human Insulin-like Growth Factor-II (IGF-II) A Domain to Type 2 IGF Receptor Binding Specificity,”Growth Factors, 19:163-173 (2001).
Friden et al., “Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier,”Proc. Natl. Acad. Sci. USA, 88:4771-4775 (Jun. 1991).
Fukuta et al., “Insulin Fragments as a Carrier for Peptide Delivery Across the Blood-Brain Barrier,”Pharmaceutical Research, 11(12):1681-1688 (1994).
Godar et al., “M6P/IGII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-β1,”European Journal of Immunology, 29:1004-1013 (1999).
Grimme et al., “Endocytosis of Insulin-like Growth Factor II by a Mini-receptor Based on Repeat 11 of the Mannose 6-Phosphate/Insulin-like Growth Factor II Receptor,”The Journal of Biological Chemistry, 275(43):33697-33703 (Oct. 27, 2000).
Hashimoto et al., “N-terminal Deletion Mutants of Insulin-like Growth Factor-II (IGF-II) Show Th

Affiliated with

Also associated with

Rating

Subcellular targeting of therapeutic proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Subcellular targeting of therapeutic proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Subcellular targeting of therapeutic proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3967835